drug · antibody drug conjugate
izalontamab brengitecan
Phase 3updated 3mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Phase 3community read0 votes
Antibody drug conjugate drug with a maximum clinical stage of Unknown, with 1 investigational indication.
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
News(3)
- Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad ideaCombining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…fiercebiotech · 11d ago
- BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this yearBMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.fiercebiotech · 15d ago
- ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing StudiesExperts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 3mo ago
Data sources
last refreshed 47m ago
Found something off?
comments(0)
5-min edit window · permanent after that